Modulation of the immune response and tumor growth by activated Ras

As a result of its transforming abilities, activated Ras is expressed in a great number of cancers. The ras mutation frequency varies between 95% in pancreatic cancer and 5% in breast cancer. In leukemia, the highest frequency (30%) is found in acute myeloid leukemia. The presence of ras mutations has been correlated with a poor prognosis and negative clinical outcome. This suggests that mutated Ras activates mechanisms, which favor tumor growth, enhance the metastatic capacity of tumors or modulate tumor-specific immune responses. Several new functions of Ras, such as downregulation of major histocompatibility complex molecules, upregulation of certain cytokines, growth factors and degradative enzymes have been uncovered in the last decade. Additionally, mutated Ras can also serve as a primary target for the development of immunotherapy or drug therapy. This review will discuss the mechanisms by which Ras expressing tumors are able to evade destruction by the immune system and enhance their growth and metastatic potential. It will further elaborate on the attempts to develop successful immunotherapy and drug therapy targeting Ras expressing tumors.

[1]  L. Forman,et al.  Differential Regulation of Discrete Apoptotic Pathways by Ras* , 1998, The Journal of Biological Chemistry.

[2]  R. Offringa,et al.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Der,et al.  Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? , 1997, Biochimica et biophysica acta.

[4]  B. Seizinger,et al.  Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. , 1995, Cancer research.

[5]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[6]  Wei Chen,et al.  Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide , 1994, The Journal of experimental medicine.

[7]  Teruhiko Yoshida,et al.  Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. , 1995, Cancer research.

[8]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[9]  J. Roth,et al.  Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. , 1996, Cancer gene therapy.

[10]  J. Schlom,et al.  Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses , 1996, European journal of immunology.

[11]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[12]  A. Wittinghofer,et al.  The interaction of Ras with GTPase‐activating proteins , 1997, FEBS letters.

[13]  D. Taub,et al.  Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. , 1993, Journal of the National Cancer Institute.

[14]  C. Chen,et al.  N-RAS oncogene mutations in patients with agnogenic myeloid metaplasia in leukemic transformation. , 1998, Leukemia research.

[15]  P. Schrier,et al.  ras oncogene activation does not induce sensitivity to natural killer cell-mediated lysis in human melanoma. , 1994, The Journal of investigative dermatology.

[16]  J. Myklebust,et al.  Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21‐ras (12VAL) peptide vaccination of a patient, recognize 12VAL‐dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation , 1997, International journal of cancer.

[17]  D. Byrd,et al.  CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. , 1995, Cancer research.

[18]  Chih-Yi Chen,et al.  Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome , 1998, Journal of Cancer Research and Clinical Oncology.

[19]  L. Donehower,et al.  Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. , 1993, Human gene therapy.

[20]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[21]  D. Hoelzer,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia , 1995, Current opinion in hematology.

[22]  H. Pehamberger,et al.  Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. , 1997, Cancer Research.

[23]  S. Sebti,et al.  Farnesyltransferase as a target for anticancer drug design. , 1997, Biopolymers.

[24]  J. Neefjes,et al.  Cell biology of antigen presentation. , 1993, Current opinion in immunology.

[25]  D. Peace,et al.  T‐Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR‐ABL a , 1993, Annals of the New York Academy of Sciences.

[26]  J. Radich,et al.  N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. , 1990, Blood.

[27]  T. Jacks,et al.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells , 1996, Nature Genetics.

[28]  A. Børresen-Dale,et al.  Ki-ras mutations and prognosis in colorectal cancer. , 1998, European journal of cancer.

[29]  F. Larcher,et al.  Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. , 1996, Cancer research.

[30]  R. Weinberg,et al.  N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma , 1986, Cell.

[31]  C. Nies,et al.  K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. , 1998, Annals of surgery.

[32]  J. Benhattar,et al.  Prognostic significance of K-ras mutations in colorectal carcinoma. , 1993, Gastroenterology.

[33]  E. Thorsby,et al.  Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation , 1995, The Lancet.

[34]  O. Cochet,et al.  Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. , 1998, Cancer research.

[35]  H. Stauss,et al.  Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein , 1993, The Journal of experimental medicine.

[36]  B. Seliger,et al.  Multiple Levels of MHC Class I Down‐Regulation by ras Oncogenes , 1996, Scandinavian journal of immunology.

[37]  A. Kral,et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.

[38]  M. Malumbres,et al.  Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. , 1998, Cancer research.

[39]  W. Kast,et al.  Induction and characterization of cytotoxic T‐lymphocytes recognizing a mutated p21ras peptide presented by HLA‐A*0201 , 1995, International journal of cancer.

[40]  R. Stahel.  Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer. , 1994, Lung cancer.

[41]  W. Fantl,et al.  Platelet-derived growth factor receptor mediates activation of ras through different signaling pathways in different cell types , 1993, Molecular and cellular biology.

[42]  F. Costa,et al.  N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. , 1997, Leukemia & lymphoma.

[43]  A. Pellicer,et al.  Differential expression of the ras gene family in mice , 1987, Molecular and cellular biology.

[44]  T. Kielian,et al.  Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice , 1998, Cancer Immunology, Immunotherapy.

[45]  A. S. Bajkowski,et al.  Differences in targeting and secretion of cathepsins B and L by BALB/3T3 fibroblasts and Moloney murine sarcoma virus-transformed BALB/3T3 fibroblasts. , 1990, The Journal of biological chemistry.

[46]  Y. Hayashi,et al.  Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. , 1997, Leukemia research.

[47]  A. Hall,et al.  A biochemical function for ras--at last. , 1994, Science.

[48]  A. Anichini,et al.  Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. , 1994, Cancer research.

[49]  D. Lowy,et al.  Function and regulation of ras. , 1993, Annual review of biochemistry.

[50]  E. Hafen,et al.  Ras--a versatile cellular switch. , 1998, Current opinion in genetics & development.

[51]  G. Prendergast,et al.  Ras regulatory interactions: Novel targets for anti‐cancer intervention? , 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.

[52]  H. Schluesener,et al.  Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins , 1991, The Journal of experimental medicine.

[53]  P. Hand,et al.  Mutant ras epitopes as targets for cancer vaccines. , 1996, Seminars in oncology.

[54]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[55]  D. Spandidos,et al.  Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value , 1997, Annals of Hematology.

[56]  J. Fagerberg,et al.  Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen , 1998, Cancer Immunology, Immunotherapy.

[57]  M. L. M. Silva,et al.  Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome. , 1998, Leukemia research.

[58]  N. Kohl,et al.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.

[59]  P. Bunn,et al.  Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. , 1998, Cancer research.

[60]  R. Offringa,et al.  An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. , 1995, Journal of immunology.

[61]  F. Al-Mulla,et al.  Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality , 1998, The Journal of pathology.

[62]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[63]  D. Largaespada,et al.  Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia , 1996, Nature Genetics.

[64]  Z. A. Trapeznikova.  On the Interaction of , 1959 .

[65]  C. Stiller,et al.  population-based UKCCSG study , 1994 .

[66]  Wei Chen,et al.  T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. , 1991, Journal of immunology.

[67]  F. McCormick,et al.  N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. , 1993, Blood.

[68]  Y. Tsujimoto,et al.  Modulation of LFA-1 surface antigen expression by activated H-ras oncogene in EBV-infected human B-lymphoblast cells. , 1991, Oncogene.

[69]  J. Schlom,et al.  Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21 , 1995, European journal of immunology.

[70]  W. L. Shupert,et al.  Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. , 1998, Cellular immunology.

[71]  J. Schlom,et al.  Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. , 1997, Cellular immunology.

[72]  L. Tentori,et al.  Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene. , 1997, Journal of experimental & clinical cancer research : CR.

[73]  S. Segal,et al.  The effect of H-ras expression on tumorigenicity and immunogenicity of Balb/c 3T3 fibroblasts. , 1993, Immunology letters.

[74]  R. Offringa,et al.  Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. , 1998, Journal of immunology.

[75]  F. White,et al.  VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation--evidence for divergent stabilization pathways. , 1997, Growth factors.

[76]  E. Thorsby,et al.  T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. , 1992, Human immunology.

[77]  S. Orlow,et al.  Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v‐rasHa oncogene , 1996, International journal of cancer.

[78]  A. Craig,et al.  Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. , 1994, Cancer research.

[79]  M. Toi,et al.  Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion , 1989, International journal of cancer.

[80]  J. Roth,et al.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. , 1991, Cancer research.

[81]  B. Hill,et al.  Inhibitors of the Ras signal transduction pathway as potential antitumour agents. , 1996, Journal of enzyme inhibition.

[82]  M. Benito,et al.  Genetic abnormalities and microsatellite instability in colorectal cancer. , 1998, Cancer detection and prevention.

[83]  T. Kuo,et al.  Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas , 1998, International journal of cancer.

[84]  G. Prendergast,et al.  Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. , 1996, Cancer research.

[85]  T. Sayers,et al.  Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. , 1998, Cancer research.

[86]  C. Martínez-A,et al.  Ras activation leads to cell proliferation or apoptotic cell death upon interleukin‐2 stimulation or lymphokine deprivation, respectively , 1997, European journal of immunology.

[87]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[88]  D. De Rijk,et al.  Invasive and metastatic capacity of revertants of LFA-1-deficient mutant T-cell hybridomas. , 1990, Cancer research.

[89]  A. Chambers,et al.  Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras‐transformed NIH 3T3 cells , 1992, Molecular carcinogenesis.

[90]  I. Sánchez-García,et al.  Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. , 1997, Journal of molecular biology.

[91]  G. Gaudernack,et al.  Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells , 1993, European journal of immunology.

[92]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[93]  R. Versteeg,et al.  c‐myc down‐regulates class I HLA expression in human melanomas. , 1988, The EMBO journal.

[94]  G. Demetri,et al.  Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. , 1990, The Journal of clinical investigation.

[95]  R. Offringa,et al.  Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. , 1996, Journal of immunology.

[96]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[97]  Bonnie F. Sloane,et al.  Oncogenic c-Ki-ras but Not Oncogenic c-Ha-ras Up-regulates CEA Expression and Disrupts Basolateral Polarity in Colon Epithelial Cells* , 1997, The Journal of Biological Chemistry.

[98]  G. Gaudernack,et al.  Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer , 1998, Vox sanguinis.